van Brummelen, Emilie M. J.
Levchenko, Evgeny
Dómine, Manuel
Fennell, Dean A.
Kindler, Hedy L.
Viteri, Santiago
Gadgeel, Shirish
López, Pilar Garrido
Kostorov, Vladimir
Morgensztern, Daniel
Orlov, Sergey
Zauderer, Marjorie G.
Vansteenkiste, Johan F.
Baker-Neblett, Katherine
Vasquez, James
Wang, Xiaowei
Bellovin, David I.
Schellens, Jan H. M.
Yan, Li
Mitrica, Ionel
DeYoung, M. Phillip
Trigo, José http://orcid.org/0000-0002-4489-2683
Funding for this research was provided by:
GlaxoSmithKline Inc.
Article History
Received: 10 March 2019
Accepted: 12 April 2019
First Online: 7 May 2019
Compliance with ethical standards
:
: M. Dómine reports receiving speakers’ bureau honoraria and is a consultant/advisory board member for AstraZeneca (AZ), Bristol-Myers Squibb (BMS), Boehringer Ingelheim (BI), Celgene, MSD, Roche-Genentech, and AbbVie.D.A. Fennell reports receiving commercial research grants from Astex, Bayer, and BI, speakers’ bureau honoraria from BI and BMS and is a consultant/advisory board member for Roche, Bayer, Aldeyra Therapeutics, AbbVie, and BMS.H.L. Kindler reports receiving commercial research grants from Aduro Biotech, AZ, Bayer, GlaxoSmithKline (GSK), Merck, MedImmune, Verastem, BMS, Eli Lilly, Polaris, and Deciphera and is a consultant/advisory board member for Aduro Biotech, MedImmune, Bayer, Celgene, GSK, AZ, Merck, BMS, BI, Ipsen, Erytech Pharma, Five Prime Therapeutics, and Paredox Therapeutics.S. Gadgeel is a consultant/advisory board member for AZ, Roche-Genentech, Takeda, BMS, and AbbVie.P. Garrido Lopez reports receiving commercial research grants from GSK, Celgene, Sanofi, PharmaMar, Theradex, Roche, BMS, Lilly, Guardant, Sysmex, Takeda, AZ, BI, and Novartis and is a consultant/advisory board member for Roche, MSD, BMS, BI, Pfizer, Abbvie, Guardant,Novartis, Lilly, AZ, Janssen, Sysmex, Blueprint Medicine, and Takeda.D. Morgensztern is a consultant/advisory board member for Takeda, AbbVie, BMS, and PharmaMar.M.G. Zauderer is an employee of MSKCC and MSKCC has an institutional collaboration agreement with IBM for Watson for Oncology and receives royalties from IBM, is the Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, reports receiving commercial research grants from MedImmune, Epizyme, Polaris, Sellas Life Sciences, BMS, and Millenium, and is a consultant/advisory board member for Epizyme and Aldeyra Therapeutics.J.F. Vansteenkiste reports receiving research funding/honoraria from MSD, AZ, BMS, BI, and Roche and is a consultant/advisory board member for AZ, BMS, BI, MSD, and Roche.K. Baker-Neblett, X. Wang, L. Yan, I. Mitrica, and M.P. DeYoung are employees of and hold ownership interest in GlaxoSmithKline. J. Vasquez is an employee of GlaxoSmithKline.D.I. Bellovin is an employee of and holds ownership interest in Five Prime Therapeutics.J.H.M. Schellens is an employee of and holds ownership interest in Modra Pharmaceuticals and is a consultant/advisory board member for Debiopharm.J.M. Trigo reports receiving speakers’ bureau honoraria from BMS and BI and is a consultant/advisory board member for BMS, BI, Merck, and Takeda.No potential conflicts of interest were disclosed by the other authors.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.